Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
When people research regenerative medicine, most articles focus on what a treatment might offer. A balanced decision also requires understanding the possible downsides. This article explains how international patients can think about the risks and side effects of adipose-derived stem cell therapy, and which questions are worth bringing to a consultation at Grand Green Osaka Umekita Clinic in Osaka, Japan.
The short answer: every step has its own risks
Adipose-derived stem cell therapy is a multi-step process. A small amount of your own fat tissue is collected, mesenchymal stem cells are cultured and expanded at a specialized facility, and the cells are later returned to your body by IV infusion. Each step is a different medical procedure, so each can carry its own possible risks. No treatment is free of risk, and no one can promise a particular result or the absence of side effects. The most useful approach is to learn what is generally reported, then ask your physician how it applies to your own health.
This treatment is offered in Japan as a self-pay (non-insured) medical service. It is provided under Japan’s regenerative medicine safety law, and the details of costs, risks, side effects, and whether the treatment is suitable for you must be confirmed in a consultation with a doctor.
Risks related to the fat collection
The first step is a minor procedure performed under local anesthesia, in which only a small amount of fat tissue is collected through a small incision. Like other minor procedures, it can be associated with temporary discomfort, bruising, swelling, or bleeding at the collection site. Infection and reactions to local anesthetic are also possible in principle. Your doctor can explain how the area is cared for afterward and what signs, such as increasing redness, heat, or pain, should prompt you to contact the clinic.
If you take blood-thinning medication, have a bleeding tendency, or have had a past reaction to anesthesia, tell the clinic in advance. These details can change how a procedure is planned.
Risks related to the cells and the infusion
Because the treatment uses your own cells, the risk of rejection or allergic reaction is generally considered lower than with donor cells or artificial materials. Lower does not mean absent. Published reviews of intravenous mesenchymal stem cell therapy describe mostly mild and temporary reactions, such as fever, chills, or discomfort around the infusion, while also noting that study designs, cell types, and patient groups vary widely. A single study should never be read as a guarantee about any individual.
Infusion through a vein also carries the ordinary risks of an IV drip, such as bruising at the needle site or, rarely, infection. Useful questions include how patients are monitored during and after infusion, how long you will be observed in the clinic, and what happens if a reaction occurs.
Another area to understand is the culture process. Cells are grown outside the body, so quality control matters. You can ask how the processing facility is managed, what safety checks are performed on the cells before they are returned to you, and how these arrangements are described in the plan submitted under Japanese law.
What is still uncertain
Research on mesenchymal stem cells is active worldwide, but many questions remain open. Long-term safety data are limited for some uses, and results from laboratory or animal studies do not automatically apply to people. Effects reported in one group of patients may not occur in another, and responses can differ from person to person. Be cautious about any source, including a clinic website, that presents this field as settled or presents outcomes as certain.
Stem cell therapy should also not be understood as a replacement for standard medical care. If you are being treated for a condition, continue to work with your regular doctors, and discuss any plan to add or change treatment with them.
Questions to bring to your consultation
Preparing a short list of questions helps you make the most of the appointment, especially if you are traveling and communicating in a second language. Consider asking:
- What are the possible risks and side effects of each step, from fat collection to infusion?
- Based on my health history and medications, are there reasons this might not be suitable for me?
- How will I be monitored after the infusion, and who do I contact if I feel unwell after returning home?
- What is the total cost, including any additional visits, and what is included in the quoted price?
- How is the treatment provided under Japan’s regenerative medicine framework?
Write down the answers, and ask for key documents in a language you can read. It is reasonable to take time to decide after the consultation rather than on the same day.
Planning ahead as an international patient
Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and has an information page for international patients in multiple languages. Because the process involves more than one visit, think about how a possible reaction after your flight home would be handled, and whether your local doctor can be informed about your treatment. Sharing your medical records and current medication list before the consultation helps the doctor assess your situation more accurately.
In summary, adipose-derived stem cell therapy involves several procedures, each with possible risks, and the long-term picture is still being studied. Asking direct questions about safety, costs, and follow-up, and confirming everything with a physician in person, is the best way to decide whether to proceed.
- 1Fat collectionAsk about site risks
- 2Cell cultureAsk about quality checks
- 3IV infusionAsk about monitoring
- 4Doctor consultationConfirm everything in person
This figure is a conceptual summary of the article content
References
- PubMed: Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. (2022)
- PubMed: Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study. (2024)
- PubMed: Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). (2017)
- PubMed: Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae. (2025)
- PubMed: Glycocalyx-edited mesenchymal stem/stromal cell therapy in advanced osteoporosis. (2026)
- PMC: A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy. (2025)
- PMC: Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial. (2026)
- PMC: Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: a randomized controlled trial. (2023)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.